Head to Head Analysis: AEON Biopharma (NASDAQ:AEON) versus Comera Life Sciences (NASDAQ:CMRA)

Insider and Institutional Ownership

22.8% of AEON Biopharma shares are owned by institutional investors. 8.9% of Comera Life Sciences shares are owned by company insiders. Comparatively, 0.9% of AEON Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Comera Life Sciences and AEON Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Comera Life Sciences	N/A	N/A	N/A
AEON Biopharma	N/A	N/A	-994.63%

Valuation and Earnings

This table compares Comera Life Sciences and AEON Biopharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Comera Life Sciences	$1.00 million	0.00	-$18.00 million	N/A	N/A
AEON Biopharma	N/A	N/A	-$36.63 million	($6.08)	-0.13

Comera Life Sciences has higher revenue and earnings than AEON Biopharma.

Volatility and Risk

Comera Life Sciences has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.

Summary

Comera Life Sciences beats AEON Biopharma on 5 of the 6 factors compared between the two stocks.

About Comera Life Sciences

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

About AEON Biopharma

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.